These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19187079)

  • 1. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials.
    Veyrat-Follet C; Vivier N; Trellu M; Dubruc C; Sanderink GJ
    J Thromb Haemost; 2009 Apr; 7(4):559-65. PubMed ID: 19187079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.
    Trellu M; Fau JB; Cortez P; Cheng S; Paty I; Boëlle E; Donat F; Sanderink GJ
    Br J Clin Pharmacol; 2013 May; 75(5):1255-64. PubMed ID: 23078631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion.
    Paty I; Trellu M; Destors JM; Cortez P; Boëlle E; Sanderink G
    J Thromb Haemost; 2010 Apr; 8(4):722-9. PubMed ID: 20088937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.
    Equinox Investigators
    J Thromb Haemost; 2011 Jan; 9(1):92-9. PubMed ID: 20946157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
    Mueck W; Lensing AW; Agnelli G; Decousus H; Prandoni P; Misselwitz F
    Clin Pharmacokinet; 2011 Oct; 50(10):675-86. PubMed ID: 21895039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials.
    Harenberg J; Jörg I; Vukojevic Y; Mikus G; Weiss C
    Eur J Clin Pharmacol; 2008 Jun; 64(6):555-63. PubMed ID: 18283446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.
    Prandoni P; Tormene D; Perlati M; Brandolin B; Spiezia L
    Expert Opin Investig Drugs; 2008 May; 17(5):773-7. PubMed ID: 18447601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idraparinux versus standard therapy for venous thromboembolic disease.
    ; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
    N Engl J Med; 2007 Sep; 357(11):1094-104. PubMed ID: 17855670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis.
    Barrett JS; Gibiansky E; Hull RD; Planès A; Pentikis H; Hainer JW; Hua TA; Gastonguay M
    Int J Clin Pharmacol Ther; 2001 Oct; 39(10):431-46. PubMed ID: 11680668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism--the Hokusai-VTE phase 3 study.
    Niebecker R; Jönsson S; Karlsson MO; Miller R; Nyberg J; Krekels EH; Simonsson US
    Br J Clin Pharmacol; 2015 Dec; 80(6):1374-87. PubMed ID: 26218447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idraparinux sodium: SANORG 34006, SR 34006.
    Drugs R D; 2004; 5(3):164-5. PubMed ID: 15139779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idraparinux and idrabiotaparinux.
    Harenberg J
    Expert Rev Clin Pharmacol; 2010 Jan; 3(1):9-16. PubMed ID: 22111528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pentasaccharides for the treatment of deep vein thrombosis.
    Brandao GM; Junqueira DR; Rollo HA; Sobreira ML
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011782. PubMed ID: 29199766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial.
    van Doormaal FF; Cohen AT; Davidson BL; Decousus H; Gallus AS; Gent M; Piovella F; Prins MH; Raskob GE; Büller HR
    Thromb Haemost; 2010 Jul; 104(1):86-91. PubMed ID: 20508907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended prophylaxis of venous thromboembolism with idraparinux.
    ; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
    N Engl J Med; 2007 Sep; 357(11):1105-12. PubMed ID: 17855671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.
    ; Bousser MG; Bouthier J; Büller HR; Cohen AT; Crijns H; Davidson BL; Halperin J; Hankey G; Levy S; Pengo V; Prandoni P; Prins MH; Tomkowski W; Torp-Pedersen C; Wyse DG
    Lancet; 2008 Jan; 371(9609):315-21. PubMed ID: 18294998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
    Bruins Slot KM; Berge E
    Cochrane Database Syst Rev; 2013 Aug; (8):CD008980. PubMed ID: 23925867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man.
    Boneu B; Necciari J; Cariou R; Sié P; Gabaig AM; Kieffer G; Dickinson J; Lamond G; Moelker H; Mant T
    Thromb Haemost; 1995 Dec; 74(6):1468-73. PubMed ID: 8772222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers.
    Bijsterveld NR; Vink R; van Aken BE; Fennema H; Peters RJ; Meijers JC; Büller HR; Levi M
    Br J Haematol; 2004 Mar; 124(5):653-8. PubMed ID: 14871253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.
    Buller HR; Halperin J; Hankey GJ; Pillion G; Prins MH; Raskob GE
    J Thromb Haemost; 2014 Jun; 12(6):824-30. PubMed ID: 24597472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.